Syndrome myasthénique de Lambert-Eaton : le traitement par phosphate d'amifampridine est efficace et bien toléré

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4717
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

Syndrome myasthénique de Lambert-Eaton : le traitement par phosphate d'amifampridine est efficace et bien toléré

Message par Pboulanger » 12 juil. 2016 16:41

:hi:

Lu sur Orphanet http://www.orpha.net/actor/Orphanews/20 ... html#60762 et Publimed http://www.ncbi.nlm.nih.gov/pubmed/2685 ... t=Abstract

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
1. Muscle Nerve. 2016 May;53(5):717-25. doi: 10.1002/mus.25070. Epub 2016 Mar 3.

Amifampridine phosphate (Firdapse(®) ) is effective and safe in a phase 3 clinical trial in LEMS.


Oh SJ(1), Shcherbakova N(2), Kostera-Pruszczyk A(3), Alsharabati M(1), Dimachkie M(4), Blanco JM(5), Brannagan T(6), Lavrnić D(7), Shieh PB(8), Vial C(9), Meisel A(10), Komoly S(11), Schoser B(12), Sivakumar K(13), So Y(14); LEMS Study Group.

Author information:
(1)Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. (2)Research Center of Neurology, Moscow, Russia. (3)Department of Neurology, Medical University of Warsaw, Poland. (4)University of Kansas Medical Center, Kansas City, Kansas, USA. (5)Gregorio Maranon Hospital, Madrid, Spain. (6)Columbia University Medical Center, New York, New York, USA. (7)Clinical Center of Serbia, Clinic of Neurology, Belgrade, Serbia. (8)Department of Neurology, University of California, Los Angeles, California, USA. (9)Hospital of Lyon, ENMG Service and Neuromuscular Pathology Hospital, Lyon, France. (10)Charite Universitatsmedizin Berlin-NeuroCure Clinical Research Center, Berlin, Germany. (11)University of Pécs, Department of Neurology, Pécs, Hungary. (12)Ludwig-Maximilians-University Munich Friedrich-Baur-Institute, Munich, Germany. (13)Neuromuscular Research Center, Phoenix, Arizona, USA. ksiva@nrcaz.com. (14)Stanford University, Stanford, California, USA.

  • OBJECTIVE:
    We evaluated the efficacy and safety of amifampridine phosphate (Firdapse(®) ) for symptomatic treatment in Lambert-Eaton myasthenic syndrome
    (LEMS).
  • METHODS:
    Phase 3, randomized, double-blind, study. Patients were treated initially with amifampridine phosphate for 7-91 days, followed by randomization
    to continue amifampridine phosphate for 14 days or placebo (7-day taper, 7-day placebo). The primary efficacy endpoints were changes from aseline at day 14 in Quantitative Myasthenia Gravis and Subject Global Impression scores.
  • RESULTS:
    The coprimary efficacy end points and 1 of the secondary efficacy end points were met, showing a significant benefit of aminfampridine phosphate over placebo at Day 14. All 5 primary, secondary, and tertiary endpoints achieved statistical significance at Day 8. Amifampridine phosphate was well tolerated; the most common adverse events were oral and digital paresthesias, nausea, and headache.
  • CONCLUSIONS:
    This study provides Class I evidence of efficacy of amifampridine phosphate as a symptomatic treatment for LEMS.
Muscle Nerve 53: 717-725, 2016.

© 2016 Wiley Periodicals, Inc.

DOI: 10.1002/mus.25070
PMID: 26852139 [PubMed - in process]
Amicalement,
Image

Répondre

Retourner vers « Informations »